HomeCompareJDHYX vs ABBV

JDHYX vs ABBV: Dividend Comparison 2026

JDHYX yields 6.29% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $72.0K in total portfolio value
10 years
JDHYX
JDHYX
● Live price
6.29%
Share price
$7.34
Annual div
$0.46
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$939.60
Full JDHYX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — JDHYX vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJDHYXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JDHYX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JDHYX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JDHYX
Annual income on $10K today (after 15% tax)
$534.97/yr
After 10yr DRIP, annual income (after tax)
$798.66/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,257.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JDHYX + ABBV for your $10,000?

JDHYX: 50%ABBV: 50%
100% ABBV50/50100% JDHYX
Portfolio after 10yr
$66.3K
Annual income
$12,855.68/yr
Blended yield
19.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

JDHYX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JDHYX buys
0
ABBV buys
0
No recent congressional trades found for JDHYX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJDHYXABBV
Forward yield6.29%3.06%
Annual dividend / share$0.46$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$30.3K$102.3K
Annual income after 10y$939.60$24,771.77
Total dividends collected$7.9K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JDHYX vs ABBV ($10,000, DRIP)

YearJDHYX PortfolioJDHYX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,329$629.37$11,550$430.00$221.00ABBV
2$12,789$666.39$13,472$627.96$683.00ABBV
3$14,387$703.03$15,906$926.08$1.5KABBV
4$16,133$739.14$19,071$1,382.55$2.9KABBV
5$18,037$774.63$23,302$2,095.81$5.3KABBV
6$20,109$809.39$29,150$3,237.93$9.0KABBV
7$22,360$843.34$37,536$5,121.41$15.2KABBV
8$24,802$876.39$50,079$8,338.38$25.3KABBV
9$27,446$908.50$69,753$14,065.80$42.3KABBV
10$30,307$939.60$102,337$24,771.77$72.0KABBV

JDHYX vs ABBV: Complete Analysis 2026

JDHYXStock

The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in high-yield/high-risk securities rated below investment grade. Securities rated below investment grade may include their unrated equivalents or other high-yielding securities the portfolio managers believe offer attractive risk/return characteristics.

Full JDHYX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this JDHYX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JDHYX vs SCHDJDHYX vs JEPIJDHYX vs OJDHYX vs KOJDHYX vs MAINJDHYX vs JNJJDHYX vs MRKJDHYX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.